AAVS3基因治疗血友病B患者的1-2期试验
这项多中心、开放标签的1-2期试验评估了不同剂量FLT180a在重型或中型重型血友病B患者中的安全性和有效性。10例患者接受四种剂量之一的载体基因组,中位随访27.2个月时,除1例恢复凝血因子IX预防治疗外,其余患者均维持因子IX活性;5例因子IX水平正常(范围51%至78%)。结论为低剂量FLT180a可维持正常范围的因子IX水平,但需糖皮质激素联合或不联合他克莫司的免疫抑制。
要点
- 低剂量FLT180a可使血友病B患者维持正常范围的因子IX水平。
- 治疗需糖皮质激素联合或不联合他克莫司的免疫抑制。
- 肝转氨酶升高是最常见的FLT180a相关不良事件。
核心结论
- 低剂量FLT180a可观察到正常范围的持续因子IX水平,但需要糖皮质激素联合或不联合他克莫司的免疫抑制。
研究设计与样本
- 多中心、开放标签的1-2期试验,纳入重型或中型重型血友病B患者(因子IX水平≤正常值的2%)。
- 所有患者接受糖皮质激素联合或不联合他克莫司进行免疫抑制,以降低载体相关免疫反应风险。
- 26周后患者进入长期随访研究,主要终点为第26周时因子IX水平评估的安全性和有效性。
- 10例患者接受四种FLT180a剂量之一:3.84×10^11 vg/kg、6.40×10^11 vg/kg、8.32×10^11 vg/kg或1.28×10^12 vg/kg。
主要发现
- 输注后所有患者因子IX水平呈剂量依赖性升高。
- 中位随访27.2个月(范围19.1至42.4个月)时,除1例恢复因子IX预防治疗外,其余患者均维持因子IX活性。
- 截至数据截止日期(2021年9月20日),5例患者因子IX水平正常(范围51%至78%),3例为23%至43%,1例为260%。
- 报告的不良事件中约10%与FLT180a相关,24%与免疫抑制相关;肝转氨酶升高是最常见的FLT180a相关不良事件。
- 在糖皮质激素减量后延长他克莫司使用的患者中出现转氨酶晚期升高;因子IX水平高的患者发生动静脉瘘血栓形成的严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients with hemophilia B. METHODS: In this multicenter, open-label, phase 1-2 trial, we assessed the safety and efficacy of varying doses of FLT180a in patients with severe or moderately severe hemophilia B (factor IX level, ≤2% of normal value). All the patients received glucocorticoids with or without tacrolimus for immunosuppression to decrease the risk of vector-related immune responses. After 26 weeks, patients were enrolled in a long-term follow-up study. The primary end points were safety and efficacy, as assessed by factor IX levels at week 26. RESULTS: Ten patients received one of four FLT180a doses of vector genomes (vg) per kilogram of body weight: 3.84×1011 vg, 6.40×1011 vg, 8.32×1011 vg, or 1.28×1012 vg. After receiving the infusion, all the patients had dose-dependent increases in factor IX levels. At a median follow-up of 27.2 months (range, 19.1 to 42.4), sustained factor IX activity was observed in all the patients except one, who resumed factor IX prophylaxis. As of the data-cutoff date (September 20, 2021), five patients had normal factor IX levels (range, 51 to 78%), three patients had levels from 23 to 43%, and one had a level of 260%. Of the reported adverse events, approximately 10% were related to FLT180a and 24% to immunosuppression. Increases in liver aminotransferase levels were the most common FLT180a-related adverse events. Late increases in aminotransferase levels occurred in patients who had received prolonged tacrolimus beyond the glucocorticoid taper. A serious adverse event of arteriovenous fistula thrombosis occurred in the patient with high factor IX levels. CONCLUSIONS: Sustained factor IX levels in the normal range were observed with low doses of FLT180a but necessitated immunosuppression with glucocorticoids with or without tacrolimus. (Funded by Freeline Therapeutics; ClinicalTrials.gov numbers, NCT03369444 and NCT03641703; EudraCT numbers, 2017-000852-24 and 2017-005080-40.).
引用
- Chowdary P, Shapiro S, Makris M, et al. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. N Engl J Med. 2022. PMID: 35857660. doi:10.1056/NEJMoa2119913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。